Basel, Switzerland – 6 September 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today two company presentations at investor conferences in September and October.
UBS Biotechnology Private Company Virtual Symposium
The virtual conference is to be held September 20-21, 2023. Roberto Iacone, Chief Executive Officer of Alentis will participate in a fireside chat on Thursday, September 21 at 8:30 am ET.
Oppenheimer Private Healthcare Company Showcase
The conference is to be held October 11, 2023 at The Intercontinental New York Barclay Hotel. Roberto Iacone will give a company presentation at 9:00 am ET in Track 1.
About Alentis Therapeutics
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is the leading company pioneering a novel approach to modify and reverse the course of disease by targeting CLDN1, a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease.
Alentis was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in pharma-biotech hub Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US. Visit https://alentis.ch
For more information please contact: